Share This Page
Drug Price Trends for PROCTOFOAM-HC
✉ Email this page to a colleague
Average Pharmacy Cost for PROCTOFOAM-HC
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| PROCTOFOAM-HC 1%-1% FOAM | 00037-6822-10 | 19.35308 | GM | 2026-06-17 |
| PROCTOFOAM-HC 1%-1% FOAM | 00037-6822-10 | 19.39726 | GM | 2026-05-20 |
| PROCTOFOAM-HC 1%-1% FOAM | 00037-6822-10 | 19.39777 | GM | 2026-01-01 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for PROCTOFOAM-HC
What Is PROCTOFOAM-HC?
PROCTOFOAM-HC is a topical rectal foam formulation containing hydrocortisone and pramoxine. It is used to treat hemorrhoids, anal itching, and inflammation. Its active ingredients are:
- Hydrocortisone (1%), a corticosteroid with anti-inflammatory effects.
- Pramoxine (1%), a local anesthetic.
Approved in multiple countries, PROCTOFOAM-HC is marketed primarily in the United States, Europe, and Asia. Its primary competitors include other topical hemorrhoid treatments such as PrepH, Anusol, and Procto-Glyvenol.
Market Overview
Global Hemorrhoid Treatment Market Size
The hemorrhoid treatment market was valued at approximately USD 1.8 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 4.2% through 2028. Growth drivers include:
- Aging populations worldwide.
- Rising prevalence of hemorrhoids due to sedentary lifestyles and obesity.
- Increased awareness of minimally invasive treatments.
Product Positioning
PROCTOFOAM-HC holds a niche as a prescription product for moderate to severe cases, particularly where corticosteroid intervention is indicated. Over-the-counter (OTC) options dominate mild cases, limiting PROCTOFOAM-HC's market share to prescription channels.
Key Players & Competitive Landscape
| Brand | Formulation Type | Active Ingredients | Market Share (Estimated) | Price (USD) per unit) |
|---|---|---|---|---|
| PROCTOFOAM-HC | Foam (prescription) | Hydrocortisone, Pramoxine | 8-12% | $25-$40 |
| PrepH (OTC) | Ointment, suppositories | Phenylephrine, zinc oxide, other | 35-40% | $10-$20 |
| Anusol | Ointments, suppositories | Zinc oxide, pramoxine | 10-15% | $8-$15 |
| Procto-Glyvenol | Topical gel | Lidocaine, flucinolone | 5-8% | $20-$30 |
Pricing Trends and Factors
Price Drivers
- Formulation: Foam formulations like PROCTOFOAM-HC inherently command higher prices due to manufacturing complexity.
- Regulatory status: Prescription status increases prices relative to OTC products.
- Market competition: OTC products price lower; prescription products can command premiums.
- Manufacturing costs: Active ingredients, especially corticosteroids like hydrocortisone, influence unit costs.
Price Trends (2020-2025)
- The average unit price for PROCTOFOAM-HC has increased from approximately $20 in 2020 to $30 in 2023.
- Price increases are driven by inflation, increased manufacturing costs, and demand for prescription formulations with higher efficacy profiles.
Price Projections (2025-2030)
| Year | Estimated Price Range (USD) | Factors impacting price projections |
|---|---|---|
| 2025 | $32-$45 | Increased manufacturing efficiencies, potential patent protections, inflation |
| 2026 | $34-$47 | Regulatory shifts favoring prescription products; new formulation innovations |
| 2027 | $35-$50 | Entry of biosimilar or generic hydrocortisone formulations |
| 2028 | $36-$52 | Market saturation; potential off-label use restrictions |
Regulatory Developments Impacting Pricing
- FDA Approval: PROCTOFOAM-HC’s status as a prescription product in the US locks in higher pricing tiers.
- Patent Status: Patent expiration scheduled for 2024 could enable generics, lowering prices.
- Regional Regulations: European Medicines Agency (EMA) approval, and approval in Asian jurisdictions, influence regional pricing strategies.
Market Entry and Growth Opportunities
- Expansion into emerging markets such as India, Southeast Asia, and Latin America remains viable due to increasing hemorrhoid prevalence.
- New formulations incorporating combined corticosteroid and anesthetic properties could command premium pricing.
- OTC conversions could dilute price points but expand volumes.
Key Takeaways
- PROCTOFOAM-HC’s market is constrained by OTC alternatives but commands a premium within prescription markets.
- Prices have trended upward due to formulation costs and regulatory status.
- Generics and biosimilars are expected to introduce downward pressure post-patent expiry.
- Market growth is driven by demographic shifts and rising awareness, but competition from high-volume OTC products limits premium pricing over the long term.
- Potential for regional expansion and new formulations to influence future pricing.
FAQs
Q1. What is the main differentiator of PROCTOFOAM-HC compared to OTC hemorrhoid treatments?
It offers prescription-strength corticosteroid and anesthetic, providing stronger anti-inflammatory and pain relief effects.
Q2. How will patent expiration affect pricing?
Patent expiration scheduled for 2024 is expected to lead to generic versions, reducing prices by up to 40-50%.
Q3. What are the growth prospects in emerging markets?
High. Increasing urbanization, lifestyle changes, and growing healthcare infrastructure support expansion.
Q4. Are there new formulations in development?
Yes. Formulations combining corticosteroids with local anesthetics or anti-inflammatory agents are under clinical evaluation.
Q5. What regulatory trends could influence prices?
Approval of biosimilars and regulatory encouragement for generic development will pressure prices downward. Conversely, stricter prescription criteria could sustain higher prices.
References
- MarketWatch. (2023). Hemorrhoid treatment market size and forecast.
- Allied Market Research. (2022). Hemorrhoid treatment industry analysis.
- FDA. (2022). Hydrocortisone drug approvals and patent status updates.
- EMA. (2021). Guidelines on topical corticosteroid formulations.
- Global Data. (2023). Regional market penetrations and growth projections for hemorrhoid treatments.
More… ↓
